Method for eradication of infection heliobacter pylory in stomach

FIELD: gastroenterology.

SUBSTANCE: eradication of infection Heliobacter pylory in stomach comprises oral administration of corresponding drugs in powdered form mixed with orange juice. In particular, mixture of colloidal bismuth subcitrate (De-nol), Nifuratel (Macmirror), and Amoxycyllin (Flemoxin solutab) are used. Administration is performed on an empty stomach at least 30-40 min before the food intake. Patient then lies at least 30 min on the both sides alternatively.

EFFECT: suppressed water-repellent property of near-wall layer of stomach mucus and slowed down evacuation of liquid from stomach thereby ensuring fast diffusion of therapeutical substances into infect persisting zone and, therefore, direct bactericidal effect on Heliobacter pylory.

4 cl


The invention relates to medicine, namely to gastroenterology and can be used for eradication of Helicobacter pylori infection in the stomach.

There is a method of eradication of Helicobacter pylori infection in the stomach by applying antibiotic therapy, accepted for similar [1].

Eradication lets not less than 80% of cases to achieve the destruction of H. pylori infection with a strict control over the regime of medication. However, in polyclinic conditions, as a rule, the percentage of eradication does not exceed 65%, at least 20 years of H. pylori era” did not create any specific drug, effectively acting on H. pylori directly in the zone of its existence, that is, in a wall surface mucus of the stomach. In clinical practice, there are only different combinations of less than ten drugs intended for the treatment of pneumonia, vaginal infections, etc. in Addition, most of these drugs are well absorbed in the small intestine, then create certain therapeutic concentrations in the tissues of the body, is highest in those authorities, for the treatment of diseases which these drugs were developed. Most antibiotics do not excretiruyutza in the stomach or appear in it at extremely low concentrations (0.1-1.0 mg/l), not affecting the livelihoods of infecta. A tablet form of H. pylori drug is in, taken on an empty stomach, can effectively influence H. pylori on the limited surface of the pyloric stomach, which is insufficient for complete eradication. Commonly prescribed by doctors for the relief of pain syndrome isolated receiving antisecretory drugs without protivoallergennyh drugs contributes to the transformation of the bacteria Helicobacter pylori in coccoid forms, more resistant to antibiotics. The use of antibiotics as monotherapy in the treatment of pneumonia and other infections contributes to polyvalent resistance in strains of H. pylori, if this infection is present in the stomach of the patient. At present in Russia for more than 15-20% of H. pylori strains resistant to clarithromycin and the stability of infecta to metronidazole has already reached 55,5%. Edinstvennim antibiotic that H. pylori resistance does not occur. is amoxicillin.

There is a method of eradication of Helicobacter pylori infection in the stomach, based on the use of tablet forms of drugs, mainly antibiotics, in various combinations. In accordance with Russian and international recommendations H. pylori therapy of patients with newly diagnosed H. pylori-associated acid pathology is carried out using two antibiotics in pill form in standard dose (CL is rythromycin + amoxicillin or clarithromycin + metronidazole) at the background of the drug inhibiting the secretion of hydrochloric acid by the stomach blockers H +/K+- At-phase (proton pump inhibitors or H2-histamine receptors of parietal cells. When an unsuccessful attempt eradication instead of the above-mentioned ternary diagrams, so-called “quadrature”, which include the same (clarithromycin, metronidazole) or previously unused (tetracycline) antibiotics and bismuth preparations (De-Nol). This method is adopted for the prototype [2].

As is known, the main habitat Helicobacfer pylori is the parietal layer of mucus of the stomach, which is a viscous, elastic, waterproof glycoprotein gel, which is the secret of surface epithelial cells (3]. The water resistance or water repellency luminale the surface of this layer is caused not only by a monolayer of surfactant formed from a variety of phospholipids, but also by the positive charge of the surface [4]. Water repellency of the surface mucous layer contribute to the slow diffusion layer of the dissolved particles, which significantly reduces the effectiveness of eradication therapy when using a tablet forms of drugs.

The aim of the present invention is to increase the effectiveness of eradication of H. pylori in the stomach with HP-associated acid diseases by providing drug interaction maximum is the horse of the mucous membrane of the stomach; the rapid diffusion of drugs in the layer of mucus in the area of persistence of infecta; direct bactericidal effect on Helicobacter pylori. This technology should lead to reliable destruction of infecta in the shortest possible time and with less material costs.

The technical result is achieved by the fact that medicines for eradication in powdered form, mixed with orange juice in a ratio of 1.0 g 90-100 ml and use this solution 2 times a day for half an hour before a meal, after 30-40 min after administration of antisecretory tools.

The powdered form of the drug promotes more rapid dissolution in orange juice. Orange juice contains citric acid, inhibits the evacuation of fluid from the stomach, thereby increasing the time of drug-drug interactions with the mucosal surface. In addition, the organic components of the juice, having a pronounced absorption capacity, are strongly linked with luminaries surface layer of mucus that neutralizes the charge and eliminating its hydrophobic properties, facilitate the diffusion of a solution of the drug into the layer depth in the area of persistence of infecta.

To test the reliability of the liquid technology eradication in the treatment of gastric ulcer or duodenal ulcer and chronic gastritis, we used four is componentry scheme, consisting of a blocker of H2-histamine receptors (famotidine 20-40 mg 2 times a day), two antibiotics (colloidal bismuth subcitrate 240 mg twice a day, nifuratel or furazolidone 200 mg twice a day) and one antibiotic, which is not produced resistance (amoxicillin 1000 mg twice a day). To enhance the effect of H. pylori funds and increasing the percentage of eradication can be used and 3-4 other component of the schema used in the hospital and giving during normal reception of tabloids maximum effect in the region (place of residence).

The method is implemented as follows.

Conduct standard clinical, laboratory examination and testing for the presence or absence of Helicobacter pylori infection in the stomach using rapid urease, cytological, histological, respiratory urease tests.

During diagnostic procedures not used any antibiotics and antisecretory drugs because they can cause bacillary-coccal transformation infect or to the appearance of the resistance. During this period, to reduce dyspepsia and relieving pain using only antacid.

When evidence of eradication of Helicobacter pylori infection in patients receiving antisecretory the x drugs (antagonists, proton pump or H2 histamine receptors of parietal cells) in the standard dosage prescribed 2 or 3 antimicrobial agents, which gives the best results in the region. On an empty stomach, morning and evening, for 40-60 minutes before a meal, the patient takes the pill antisecretory drug with a small amount of liquid. Then take a pill of H. pylori drugs in the required dosage, crushed to tankodesantniki powder, dissolved in 120-150 ml of orange juice in the ratio of 1.0 g of medicines at 90-100 ml of Prepared mix drink for 30 minutes before a meal. After taking a mixture of the patient takes a sleeping position, turning every 2-4 min from side to side. After 30 minutes the patient can eat. Eradication therapy lasts for one week. The control determination of H.pylori carried out in the same manner after 4 weeks after receiving H. pylori and antisecretory drugs.

Clinical testing of the proposed method of eradication (liquid technology) was conducted with a 7-day course of treatment in 100 patients with chronic gastritis and peptic ulcer disease, and 50 patients with similar 4-day course. Was used above quadruple regimen: famotidine, De-Nol, nifuratel or furazolidone, amoxicillin (Flemoxin Solutab). When both modes (4 or 7 days) was achieved 100% eradication of Helicobacter pylori infection, whereas when using the such schemes tablets eradication does not exceed 80-90%.

Follow-up monitoring during the year for a large group of patients showed no acute illness. The results confirm a significant increase in the efficiency of eradication when using liquid technology of reception of H. pylori funds, reduction of terms of treatment and reduce financial costs.

Sources of information

1. Zakharova NV // Consilium medicum. Gastroenterology, Annex No. 2 of 2004.-c.7-10.

2. Ivashkin V.T., Isakov V.A. // Russian J.-L. gastroenterology, Hepatology. of Coloproctology. -2001, №3.-p.1-11.

3. Krivova N.A., Dambai GC, Hitehead VE Adamically mucosal layer of the gastrointestinal tract and its functional significance. Tomsk, 2002, 315 str. Hills VA, L.M. Lichtenberger // Amer. J. PhisioL-1985.-V.248, No.6, Pt.1.-P.643-647.

1. The method of eradication of Helicobacter pylori infection in the stomach, including the introduction of medicines, characterized in that the medicinal product is used in powder form, mixed with orange juice.

2. The method according to claim 1, characterized in that the reception of a mixture of medicines with orange juice exercise on an empty stomach at least 30-40 minutes before a meal.

3. The method according to claim 1, characterized in that after each use, mix the medicine with orange juice the patient lies 30 minutes, turning from side to side.

4. The method of eradication according to claims 1 to 3, trichosis fact, that mixed with orange juice using colloidal bismuth subcitrate (De-Nol), nifuratel (Macmiror) and amoxicillin (Flemoxin Solutab).


Same patents:

FIELD: medicine.

SUBSTANCE: peptide of the following formula: X-Pro-Gly-P, where X = Thr-Lys-Pro-Arg-; Lys-pro-Arg-; pro-Arg-; Arg-, being of untiulcerous activity. They should be applied at intraperitoneal injection at the dosage of 0.58-3.20 mcM g/kg for preventing and treating ulcers of gastro-intestinal tract.

EFFECT: higher efficiency and prophylaxis.

4 dwg, 5 ex

FIELD: medicine, gastroenterology.

SUBSTANCE: traditional eradication therapy should be supplemented with licopid at the dosage of 10 mg per os once daily before breakfast for 10 d. The present innovation prevents transfer of microorganisms into inactive form, accelerates restoration of mucosal epithelial layer in gastroduodenal area, provides complete eradication of microorganisms, that in its turn, favors to prevent disease exacerbation and restoration of gastroduodenal functions.

EFFECT: higher efficiency of therapy.

3 dwg, 2 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with peroral liquid compositions which could be designed into gelatinous capsules. The suggested pharmaceutical composition includes a pharmaceutically active agent, a solubilizing agent and, not obligatory, a surface-active substance and a plastifying agent. The pharmaceutically active agent has got, at least, one acidic fragment, preferrably, that of carbonic acid being chosen out of the group of non steroid antiphlogistic preparations being acid-soluble at acid : dissolved substance ratio being from 3:1 to 10000:1. New compositions provide increased rates and degrees of absorption of pharmaceutically active agent and minimize side effects caused by such active substances.

EFFECT: higher efficiency of application.

42 cl, 39 ex

FIELD: medicine.

SUBSTANCE: method involves applying eradicative anti-helicobacterial therapy comprising Omeprazol administration at a dose of 20 mg twice a day and Ximedone at a dose of 500 mg twice a day in 12 days long course.

EFFECT: enhanced effectiveness of eradication; reduced adverse side effects risk.

FIELD: medicine, gastroenterology.

SUBSTANCE: invention relates to methods for treatment of chronic helicobacter pylori-associated gastritis. Method is carried out by monotherapy with the probiotic "Laminolakt" in the dose 3 dragees per 24 h for 1 month. Method provides elimination of Helicobacter pylori cells on the background of activation of the immune response in stomach mucosa by effect on microflora and the colon intestine immune system.

EFFECT: enhanced effectiveness of treatment.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves introducing endoscope, clearing injured surface and applying gel produced on Tisol substance base (aqua-complex of titanium glycerosolvate) as medicinal composition via the endoscope. Tisol is administered as aqueous solution of concentration not less than 60% after Tisol. The composition is applied to injured surface in the amount of 2 to 8 ml for one session. The number of treatment sessions is equal to 1 to 7 with 3-5 days long pauses. The composition is prepared by mechanically mixing medicinal microadditives with Tisol substance. The medicinal microadditives are introduced in total amount of 7.26% of composition mass. The ingredients are selected depending on disease. The medicinal composition is applied as 1-2 mm thick layer. When treating the cases of erosion or gastritis, sea-buckthorn oil and/or propolis solution are of preference to be introduced into Thysol as the medicinal microadditives. When treating the cases of gastric or duodenal peptic ulcer, methyluracyl, hydrocortisone, cycloferon or aecol are preferentially introduced into Tisol as the medicinal microadditives. The composition formula is adjusted from session to session on the basis of treatment results visual control and analysis data. Taking meals and drinks is restricted for a patient for half an hour or longer.

EFFECT: enhanced effectiveness in administering drugs into mucous membrane and soft tissues without using needle injectors.

5 cl,4 tbl

The invention relates to a device for slowing the passage through the pylorus introduced oral dosage forms

The invention relates to pharmaceutical industry and relates to the preparation of dalargin for injection, used as a medicine in the acute gastric ulcer and duodenal ulcer, acute pancreatitis and pancreonecrosis

The invention relates to heterocyclic compounds with substituted phenyl group of formula Ior its pharmaceutically acceptable salt, in which R1represents a C1-C6alkyl; R2represents a C1-C6alkyl; R3represents H or halogen andrepresents a substituted heterocycle, as defined in paragraph 1 of the claims; and X represents NH or O

The invention relates to pharmaceutical

FIELD: medicine, antibiotics.

SUBSTANCE: invention relates to cephalosporin antibiotic - cefuroximaxetil that is used in treatment of bacterial infections. Invention proposes a new form of cefuroximaxetil not forming gel in contact with an aqueous solution. New form represents a solid solution of cefuroximaxetil in polymer and/or solid dispersion on adsorbent. New form of cefuroximaxetil can be used for preparing a granulate that can be used in oral pharmaceutical compositions as tablets or powder. Exclusion of gel-formation allows improving solubility of cefuroximaxetil that results to enhancing absorption of cefuroximaxetil in digestive tract.

EFFECT: improved pharmaceutical properties of combinations.

23 cl, 3 dwg, 8 tbl, 19 ex

FIELD: medicine, cardiology, pharmacy.

SUBSTANCE: invention relates to carvedilol-containing pharmaceutical composition that is used for treatment and/or prophylaxis of hypertension, cardiac insufficiency or stenocardia. The composition comprises carvedilol or its pharmaceutically acceptable salt and one or some adjuvants. Carvedilol is distributed in adjuvants as a molecular dispersion. Adjuvants are not surface-active substance and/or non-ionogenic surface-active substance. The concentration of adjuvants exceeds 5 wt.-%. Also, invention describes a method for preparing the composition and pharmaceutically acceptable solid formulation for oral administration. Compositions of the present invention provide the enhancing solubility of carvedilol and level of its absorption in lower regions of intestine.

EFFECT: improved and valuable pharmaceutical properties of composition.

17 cl, 9 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a composition eliciting an antibacterial effect. Composition comprises hydrophilic conglomerate of immunoglobulins consortium adsorbed with polyethylene glycol 4000-6000 and a special additive taken among the following substances: glycine, glucose, maltose, sodium chloride taken in the definite ratio of components. Invention provides sufficient desorption of biologically active substances in resuspending the composition eliciting an antibacterial effect and comprising consortium of immunoglobulins.

EFFECT: valuable medicinal properties of composition.

5 ex

FIELD: medicine, pharmaceutical industry and technology, pharmacy.

SUBSTANCE: invention relates to a composition eliciting an antiviral effect. The composition comprises hydrophilic conglomerate of immunoglobulins consortium adsorbed with polyethylene glycol 4000-6000, recombinant interferon-α2 and a special additive taken among the following substances: glycine, glucose, maltose, sodium chloride taken in the definite ratio of components. Invention provides elevating solubility of composition eliciting an antiviral effect and enhanced release of biologically active substances to solution.

EFFECT: valuable medicinal properties of composition.

5 ex

FIELD: medicine, pharmacology, biochemistry, pharmacy.

SUBSTANCE: invention relates to preparations reducing blood cholesterol level. Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin and their derivatives and analogs known as inhibitors of HMG-CoA-reductase are used as anti-hypercholesterolemic agents. Above mentioned active substances can be destabilized as result of effect of environment and their destruction can be accelerated in interaction with other pharmaceutical agents, such as excipients, binding agents, lubricating agents, substances promoting to slipping and disintegrating agents. Therefore, pharmaceutical components and a method for preparing a pharmaceutical preparation must be taken thoroughly to avoid above said undesirable interactions and reactions. Invention relates to inhibitor of HMG-CoA-reductase that stabilized by formation of a homogenous composition with buffer substance or an alkalinizing substance. This homogenous composition is used as an active substance in pharmaceutical preparation used for treatment of hypercholesterolemia and hyperlipidemia. Invention enhances the enhancement of stability and homogeneity of the preparation.

EFFECT: improved and valuable pharmaceutical properties of composition.

23 cl, 2 tbl, 3 dwg, 11 ex

FIELD: medicine, gastroenterology.

SUBSTANCE: one should apply food additives as tablets of oats, corn and cabbage by "Biophyt" company; moreover, to decrease motor system of biliary ducts one should apply tablets of oats, to increase motor system - tablets of corn and for total normalization of kinetics - tablets of cabbage. Treatment lasts for 10 d at the dosage of 1-2 tablets twice daily 30 min meals. The present innovation enables to normalize functional activity of biliary ducts at the background of shortened therapeutic terms.

EFFECT: higher efficiency of therapy.

4 ex

The invention relates to bistrotdepierrerue solid dosage form that dissolves in the mouth within sixty (60), more preferably thirty (30), most preferably ten (10) seconds

The invention relates to pharmaceutical compositions cefuroxime aksetila in the form of particles

The invention relates to the field of pharmacy

The invention relates to pharmaceutical industry

FIELD: organic chemistry, pharmaceutical industry, medicine.

SUBSTANCE: invention relates to new derivatives of S-substituted N-1-[(hetero)aryl]alkyl-N'-1-[(hetero)aryl]alkylisothioureas of general formula I

in form of free base and salts with pharmaceutically accepted acids, as well as racemate, individual optical isomers or mixture thereof. In formula R1, R2, R3, R4, Y and Z are as described in specification. Compounds of present invention are capable to potentiate (positively modulate) AMPA/KA glutamate receptors and simultaneously to block transmembrane currents induced by activation of NMDA glutamate receptors. Also disclosed are method for production of said compounds, including optical isomers; pharmaceutical composition; method for investigation of glutamatergic system, and method for Alzheimer's disease, treatment; as well as method for extreme retentiveness of memory by administering of effective amount of claimed compounds.

EFFECT: new pharmaceutically active compounds for Alzheimer's disease treatment.

23 cl, 1 tbl, 11 ex